Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.

Audenet F, Isharwal S, Cha EK, Donoghue MTA, Drill EN, Ostrovnaya I, Pietzak EJ, Sfakianos JP, Bagrodia A, Murugan P, Dalbagni G, Donahue TF, Rosenberg JE, Bajorin DF, Arcila ME, Hechtman JF, Berger MF, Taylor BS, Al-Ahmadie H, Iyer G, Bochner BH, Coleman JA, Solit DB.

Clin Cancer Res. 2019 Feb 1;25(3):967-976. doi: 10.1158/1078-0432.CCR-18-2039. Epub 2018 Oct 23.

PMID:
30352907
2.

Comparison of Postradical Cystectomy Ileus Rates Using GIA-80 Versus GIA-60 Intestinal Stapler Device.

Ghanaat M, Winer AG, Sjoberg DD, Poon BY, Kashan M, Tin AL, Sfakianos JP, Cha EK, Donahue TF, Dalbagni G, Herr HW, Bochner BH, Vickers AJ, Donat SM.

Urology. 2018 Dec;122:121-126. doi: 10.1016/j.urology.2018.09.010. Epub 2018 Sep 20.

PMID:
30244117
3.

Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma."

Teo MY, Bambury RM, Zabor EC, Jordan E, Al-Ahmadie H, Boyd ME, Bouvier N, Mullane SA, Cha EK, Roper N, Ostrovnaya I, Hyman DM, Bochner BH, Arcila ME, Solit DB, Berger MF, Bajorin DF, Bellmunt J, Iyer G, Rosenberg JE.

Urol Oncol. 2018 Jul;36(7):345-346. doi: 10.1016/j.urolonc.2018.05.011. Epub 2018 May 30.

PMID:
29859727
4.

Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought.

Palou J, Pisano F, Sylvester R, Joniau S, Serretta V, Larré S, Di Stasi S, van Rhijn B, Witjes AJ, Grotenhuis A, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Dalbagni G, Shariat SF, Xylinas E, Karnes RJ, Gontero P.

World J Urol. 2018 Oct;36(10):1621-1627. doi: 10.1007/s00345-018-2299-2. Epub 2018 May 2.

PMID:
29721611
5.

Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy.

Cha EK, Sfakianos JP, Sukhu R, Yee AM, Sjoberg DD, Bochner BH.

BJU Int. 2018 Oct;122(4):627-632. doi: 10.1111/bju.14242. Epub 2018 May 4.

PMID:
29633530
6.

Genomic Profile of Urothelial Carcinoma of the Upper Tract from Ureteroscopic Biopsy: Feasibility and Validation Using Matched Radical Nephroureterectomy Specimens.

Bagrodia A, Audenet F, Pietzak EJ, Kim K, Murray KS, Cha EK, Sfakianos JP, Iyer G, Singla N, Arcila M, Bochner BH, Al-Ahmadie HA, Solit DB, Coleman JA.

Eur Urol Focus. 2018 Jan 30. pii: S2405-4569(18)30006-3. doi: 10.1016/j.euf.2018.01.005. [Epub ahead of print]

PMID:
29396293
7.

Timing of blood transfusion and oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma.

Bagrodia A, Kaffenberger S, Winer A, Murray K, Vacchio M, Zheng J, Ostrovnaya I, Bochner BH, Dalbagni G, Cha EK, Coleman JA.

World J Urol. 2018 Apr;36(4):645-653. doi: 10.1007/s00345-018-2180-3. Epub 2018 Jan 17.

PMID:
29344681
8.

Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis.

Chang MT, Penson A, Desai NB, Socci ND, Shen R, Seshan VE, Kundra R, Abeshouse A, Viale A, Cha EK, Hao X, Reuter VE, Rudin CM, Bochner BH, Rosenberg JE, Bajorin DF, Schultz N, Berger MF, Iyer G, Solit DB, Al-Ahmadie HA, Taylor BS.

Clin Cancer Res. 2018 Apr 15;24(8):1965-1973. doi: 10.1158/1078-0432.CCR-17-2655. Epub 2017 Nov 27.

PMID:
29180607
9.

Clinical Outcomes of Patients With T1 Nested Variant of Urothelial Carcinoma Compared to Pure Urothelial Carcinoma of the Bladder.

Mally AD, Tin AL, Lee JK, Satasivam P, Cha EK, Donat SM, Herr HW, Bochner BH, Sjoberg DD, Dalbagni G.

Clin Genitourin Cancer. 2017 Jul 14. pii: S1558-7673(17)30199-4. doi: 10.1016/j.clgc.2017.07.002. [Epub ahead of print]

10.

The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy.

Li Q, Assel M, Benfante NE, Pietzak EJ, Herr HW, Donat M, Cha EK, Donahue TF, Bochner BH, Dalbagni G.

Eur Urol Focus. 2019 Jan;5(1):104-108. doi: 10.1016/j.euf.2017.06.013. Epub 2017 Jun 27.

PMID:
28753857
11.

Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.

Pietzak EJ, Bagrodia A, Cha EK, Drill EN, Iyer G, Isharwal S, Ostrovnaya I, Baez P, Li Q, Berger MF, Zehir A, Schultz N, Rosenberg JE, Bajorin DF, Dalbagni G, Al-Ahmadie H, Solit DB, Bochner BH.

Eur Urol. 2017 Dec;72(6):952-959. doi: 10.1016/j.eururo.2017.05.032. Epub 2017 Jun 3.

12.

DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.

Teo MY, Bambury RM, Zabor EC, Jordan E, Al-Ahmadie H, Boyd ME, Bouvier N, Mullane SA, Cha EK, Roper N, Ostrovnaya I, Hyman DM, Bochner BH, Arcila ME, Solit DB, Berger MF, Bajorin DF, Bellmunt J, Iyer G, Rosenberg JE.

Clin Cancer Res. 2017 Jul 15;23(14):3610-3618. doi: 10.1158/1078-0432.CCR-16-2520. Epub 2017 Jan 30.

13.

Prognostic value of lymph node yield during nephroureterectomy for upper tract urothelial carcinoma.

Winer AG, Vertosick EA, Ghanaat M, Corradi RB, Carlsson S, Sjoberg DD, Sankin AI, Sfakianos JP, Cha EK, Dalbagni G, Coleman JA.

Urol Oncol. 2017 Apr;35(4):151.e9-151.e15. doi: 10.1016/j.urolonc.2016.11.002. Epub 2016 Dec 5.

14.

Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors.

Bagrodia A, Lee BH, Lee W, Cha EK, Sfakianos JP, Iyer G, Pietzak EJ, Gao SP, Zabor EC, Ostrovnaya I, Kaffenberger SD, Syed A, Arcila ME, Chaganti RS, Kundra R, Eng J, Hreiki J, Vacic V, Arora K, Oschwald DM, Berger MF, Bajorin DF, Bains MS, Schultz N, Reuter VE, Sheinfeld J, Bosl GJ, Al-Ahmadie HA, Solit DB, Feldman DR.

J Clin Oncol. 2016 Nov 20;34(33):4000-4007. doi: 10.1200/JCO.2016.68.7798. Epub 2016 Sep 30.

15.

Genomic characterization of response to chemoradiation in urothelial bladder cancer.

Desai NB, Scott SN, Zabor EC, Cha EK, Hreiki J, Sfakianos JP, Ramirez R, Bagrodia A, Rosenberg JE, Bajorin DF, Berger MF, Bochner BH, Zelefsky MJ, Kollmeier MA, Ostrovnaya I, Al-Ahmadie HA, Solit DB, Iyer G.

Cancer. 2016 Dec 1;122(23):3715-3723. doi: 10.1002/cncr.30219. Epub 2016 Aug 1.

16.

Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.

Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ.

Bladder Cancer. 2016 Apr 27;2(2):165-202.

17.

Impact of Ureteroscopy Before Nephroureterectomy for Upper Tract Urothelial Carcinoma on Oncologic Outcomes.

Sankin A, Tin AL, Mano R, Chevinsky M, Jakubowski C, Sfakianos JP, Cha EK, Yee A, Friedman FM, Sjoberg DD, Ehdaie B, Coleman J.

Urology. 2016 Aug;94:148-53. doi: 10.1016/j.urology.2016.05.039. Epub 2016 May 26.

18.

Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.

Al-Ahmadie HA, Iyer G, Lee BH, Scott SN, Mehra R, Bagrodia A, Jordan EJ, Gao SP, Ramirez R, Cha EK, Desai NB, Zabor EC, Ostrovnaya I, Gopalan A, Chen YB, Fine SW, Tickoo SK, Gandhi A, Hreiki J, Viale A, Arcila ME, Dalbagni G, Rosenberg JE, Bochner BH, Bajorin DF, Berger MF, Reuter VE, Taylor BS, Solit DB.

Nat Genet. 2016 Apr;48(4):356-8. doi: 10.1038/ng.3503. Epub 2016 Feb 22.

19.

Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma.

Bagrodia A, Cha EK, Sfakianos JP, Zabor EC, Bochner BH, Al-Ahmadie HA, Solit DB, Coleman JA, Iyer G, Scott SN, Shah R, Ostrovnaya I, Lee B, Desai NB, Ren Q, Rosenberg JE, Dalbagni G, Bajorin DF, Reuter VE, Berger MF; Collaborators.

J Urol. 2016 Jun;195(6):1684-1689. doi: 10.1016/j.juro.2016.01.006. Epub 2016 Jan 14.

20.

Prognostic Genetic Signatures in Upper Tract Urothelial Carcinoma.

Li Q, Bagrodia A, Cha EK, Coleman JA.

Curr Urol Rep. 2016 Feb;17(2):12. doi: 10.1007/s11934-015-0566-y. Review.

21.
22.

Low yield of surveillance imaging after surgery for T1 kidney cancer.

Feuerstein MA, Musser JE, Kent M, Chevinsky M, Cha EK, Kimm S, Hilton WM, Sjoberg DD, Donahue TF, Vargas HA, Coleman JA, Russo P.

World J Urol. 2016 Jul;34(7):949-53. doi: 10.1007/s00345-015-1719-9. Epub 2015 Oct 28.

23.

The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin.

Gontero P, Sylvester R, Pisano F, Joniau S, Oderda M, Serretta V, Larré S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Colombo R, Briganti A, Babjuk M, Soukup V, Malmström PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Vakarakis J, Bartoletti R, Dalbagni G, Shariat SF, Xylinas E, Karnes RJ, Palou J.

BJU Int. 2016 Jul;118(1):44-52. doi: 10.1111/bju.13354. Epub 2015 Nov 6.

24.

Genomic Characterization of Upper Tract Urothelial Carcinoma.

Sfakianos JP, Cha EK, Iyer G, Scott SN, Zabor EC, Shah RH, Ren Q, Bagrodia A, Kim PH, Hakimi AA, Ostrovnaya I, Ramirez R, Hanrahan AJ, Desai NB, Sun A, Pinciroli P, Rosenberg JE, Dalbagni G, Schultz N, Bajorin DF, Reuter VE, Berger MF, Bochner BH, Al-Ahmadie HA, Solit DB, Coleman JA.

Eur Urol. 2015 Dec;68(6):970-7. doi: 10.1016/j.eururo.2015.07.039. Epub 2015 Aug 14.

25.

Radical transurethral resection alone, robotic or partial cystectomy, or extended lymphadenectomy: can we select patients with muscle invasion for less or more surgery?

Cha EK, Donahue TF, Bochner BH.

Urol Clin North Am. 2015 May;42(2):189-99, viii. doi: 10.1016/j.ucl.2015.02.003. Epub 2015 Feb 28. Review.

26.

Re: whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation.

Cha EK, Bochner BH.

Eur Urol. 2015 Feb;67(2):350-1. doi: 10.1016/j.eururo.2014.11.021. No abstract available.

PMID:
25760253
27.

Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer.

Cha EK, Eastham JA.

Urol Oncol. 2015 May;33(5):217-25. doi: 10.1016/j.urolonc.2014.11.020. Epub 2015 Jan 14. Review.

PMID:
25596644
28.

Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.

Kim PH, Cha EK, Sfakianos JP, Iyer G, Zabor EC, Scott SN, Ostrovnaya I, Ramirez R, Sun A, Shah R, Yee AM, Reuter VE, Bajorin DF, Rosenberg JE, Schultz N, Berger MF, Al-Ahmadie HA, Solit DB, Bochner BH.

Eur Urol. 2015 Feb;67(2):198-201. doi: 10.1016/j.eururo.2014.06.050. Epub 2014 Aug 1.

29.

Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients.

Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, Larré S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Kiemeney LA, Colombo R, Briganti A, Babjuk M, Malmström PU, Oderda M, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Johansson R, Frea B, Soukup V, Xylinas E, Dalbagni G, Karnes RJ, Shariat SF, Palou J.

Eur Urol. 2015 Jan;67(1):74-82. doi: 10.1016/j.eururo.2014.06.040. Epub 2014 Jul 16.

PMID:
25043942
30.

Risk factors for the development of parastomal hernia after radical cystectomy.

Donahue TF, Bochner BH, Sfakianos JP, Kent M, Bernstein M, Hilton WM, Cha EK, Yee AM, Dalbagni G, Vargas HA.

J Urol. 2014 Jun;191(6):1708-13. doi: 10.1016/j.juro.2013.12.041. Epub 2013 Dec 30.

31.

Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder.

Xylinas E, Cha EK, Khani F, Kluth LA, Rieken M, Volkmer BG, Hautmann R, Küfer R, Chen YT, Zerbib M, Rubin MA, Scherr DS, Shariat SF, Robinson BD.

J Urol. 2014 Mar;191(3):830-41. doi: 10.1016/j.juro.2013.08.048. Epub 2013 Aug 28.

PMID:
23994370
32.

Nonneoplastic renal cortical scarring at tumor nephrectomy predicts decline in kidney function.

Salvatore SP, Cha EK, Rosoff JS, Seshan SV.

Arch Pathol Lab Med. 2013 Apr;137(4):531-40. doi: 10.5858/arpa.2012-0070-OA.

PMID:
23544942
33.

Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling.

Xylinas E, Cha EK, Sun M, Rink M, Trinh QD, Novara G, Green DA, Pycha A, Fradet Y, Daneshmand S, Svatek RS, Fritsche HM, Kassouf W, Scherr DS, Faison T, Crivelli JJ, Tagawa ST, Zerbib M, Karakiewicz PI, Shariat SF.

Br J Cancer. 2012 Nov 20;107(11):1826-32. doi: 10.1038/bjc.2012.464.

34.

Accurate risk assessment of patients with asymptomatic hematuria for the presence of bladder cancer.

Cha EK, Tirsar LA, Schwentner C, Hennenlotter J, Christos PJ, Stenzl A, Mian C, Martini T, Pycha A, Shariat SF, Schmitz-Dräger BJ.

World J Urol. 2012 Dec;30(6):847-52. doi: 10.1007/s00345-012-0979-x. Epub 2012 Nov 5.

35.

Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma.

Fajkovic H, Cha EK, Xylinas E, Rink M, Pycha A, Seitz C, Bolenz C, Dunning A, Novara G, Trinh QD, Karakiewicz PI, Margulis V, Raman JD, Walton TJ, Baba S, Carballido J, Otto W, Montorsi F, Lotan Y, Kassouf W, Fritsche HM, Bensalah K, Zigeuner R, Scherr DS, Sonpavde G, Roupret M, Shariat SF.

World J Urol. 2013 Feb;31(1):5-11. doi: 10.1007/s00345-012-0939-5. Epub 2012 Sep 26.

PMID:
23011256
36.

Cost-effective treatment of low-risk carcinoma not invading bladder muscle.

Green DA, Rink M, Cha EK, Xylinas E, Chughtai B, Scherr DS, Shariat SF, Lee RK.

BJU Int. 2013 Mar;111(3 Pt B):E78-84. doi: 10.1111/j.1464-410X.2012.11454.x. Epub 2012 Sep 7.

37.

Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy.

Rink M, Park K, Volkmer BG, Xylinas E, Hansen J, Cha EK, Robinson BD, Hautmann R, Küfer R, Engel O, Chun FK, Dahlem R, Rubin MA, Shariat SF, Mosquera JM.

Urol Oncol. 2013 Nov;31(8):1716-24. doi: 10.1016/j.urolonc.2012.06.011. Epub 2012 Sep 1.

PMID:
22944196
38.

Predictors of cancer-specific mortality after disease recurrence following radical cystectomy.

Rink M, Lee DJ, Kent M, Xylinas E, Fritsche HM, Babjuk M, Brisuda A, Hansen J, Green DA, Aziz A, Cha EK, Novara G, Chun FK, Lotan Y, Bastian PJ, Tilki D, Gontero P, Pycha A, Baniel J, Mano R, Ficarra V, Trinh QD, Tagawa ST, Karakiewicz PI, Scherr DS, Sjoberg DD, Shariat SF; Bladder Cancer Research Consortium.

BJU Int. 2013 Mar;111(3 Pt B):E30-6. doi: 10.1111/j.1464-410X.2012.11433.x. Epub 2012 Sep 3.

39.

Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis.

Fajkovic H, Cha EK, Jeldres C, Robinson BD, Rink M, Xylinas E, Chromecki TF, Breinl E, Svatek RS, Donner G, Tagawa ST, Tilki D, Bastian PJ, Karakiewicz PI, Volkmer BG, Novara G, Joual A, Faison T, Sonpavde G, Daneshmand S, Lotan Y, Scherr DS, Shariat SF.

Eur Urol. 2013 Nov;64(5):837-45. doi: 10.1016/j.eururo.2012.07.026. Epub 2012 Jul 20.

PMID:
22877503
40.

Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy.

Rink M, Hansen J, Cha EK, Green DA, Babjuk M, Svatek RS, Xylinas E, Tagawa ST, Faison T, Novara G, Karakiewicz PI, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Pycha A, Comploj E, Tilki D, Bastian PJ, Chun FK, Dahlem R, Scherr DS, Shariat SF.

BJU Int. 2013 Jan;111(1):74-84. doi: 10.1111/j.1464-410X.2012.11356.x. Epub 2012 Jul 19.

41.

Risk of cancer-specific mortality following recurrence after radical nephroureterectomy.

Rink M, Sjoberg D, Comploj E, Margulis V, Xylinas E, Lee RK, Hansen J, Cha EK, Raman JD, Remzi M, Bensalah K, Novara G, Matin SF, Chun FK, Kikuchi E, Kassouf W, Martinez-Salamanca JI, Lotan Y, Seitz C, Pycha A, Zigeuner R, Karakiewicz PI, Scherr DS, Vickers AJ, Shariat SF.

Ann Surg Oncol. 2012 Dec;19(13):4337-44. doi: 10.1245/s10434-012-2499-8. Epub 2012 Jul 18.

42.

Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy.

Green DA, Rink M, Hansen J, Cha EK, Robinson B, Tian Z, Chun FK, Tagawa S, Karakiewicz PI, Fisch M, Scherr DS, Shariat SF.

BJU Int. 2013 Mar;111(3):404-11. doi: 10.1111/j.1464-410X.2012.11370.x. Epub 2012 Jul 13.

43.

Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy.

Rink M, Xylinas E, Margulis V, Cha EK, Ehdaie B, Raman JD, Chun FK, Matsumoto K, Lotan Y, Furberg H, Babjuk M, Pycha A, Wood CG, Karakiewicz PI, Fisch M, Scherr DS, Shariat SF; Upper Tract Urothelial Carcinoma Collaboration.

Eur Urol. 2013 Jun;63(6):1082-90. doi: 10.1016/j.eururo.2012.06.029. Epub 2012 Jun 22.

44.

Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy.

Shariat SF, Rink M, Ehdaie B, Xylinas E, Babjuk M, Merseburger AS, Svatek RS, Cha EK, Tagawa ST, Fajkovic H, Novara G, Karakiewicz PI, Trinh QD, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Chun FK, Sonpavde G, Joual A, Scherr DS, Gonen M.

Eur Urol. 2013 Feb;63(2):371-8. doi: 10.1016/j.eururo.2012.06.008. Epub 2012 Jun 16.

PMID:
22727174
45.

Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy.

Chromecki TF, Cha EK, Fajkovic H, Rink M, Ehdaie B, Svatek RS, Karakiewicz PI, Lotan Y, Tilki D, Bastian PJ, Daneshmand S, Kassouf W, Durand M, Novara G, Fritsche HM, Burger M, Izawa JI, Brisuda A, Babjuk M, Pummer K, Shariat SF.

BJU Int. 2013 Feb;111(2):249-55. doi: 10.1111/j.1464-410X.2012.11322.x. Epub 2012 Jun 21.

46.

Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma.

Rink M, Robinson BD, Green DA, Cha EK, Hansen J, Comploj E, Margulis V, Raman JD, Ng CK, Remzi M, Bensalah K, Kabbani W, Haitel A, Rioux-Leclercq N, Guo CC, Chun FK, Kikuchi E, Kassouf W, Sircar K, Sun M, Sonpavde G, Lotan Y, Pycha A, Karakiewicz PI, Scherr DS, Shariat SF.

J Urol. 2012 Aug;188(2):398-404. doi: 10.1016/j.juro.2012.04.009. Epub 2012 Jun 13.

PMID:
22698626
47.

Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma.

Xylinas E, Rink M, Cha EK, Clozel T, Lee RK, Fajkovic H, Comploj E, Novara G, Margulis V, Raman JD, Lotan Y, Kassouf W, Fritsche HM, Weizer A, Martinez-Salamanca JI, Matsumoto K, Zigeuner R, Pycha A, Scherr DS, Seitz C, Walton T, Trinh QD, Karakiewicz PI, Matin S, Montorsi F, Zerbib M, Shariat SF; Upper Tract Urothelial Carcinoma Collaboration.

Eur Urol. 2014 Jan;65(1):210-7. doi: 10.1016/j.eururo.2012.04.052. Epub 2012 May 4.

PMID:
22579047
48.

Role of magnetic resonance imaging in bladder cancer: current status and emerging techniques.

Green DA, Durand M, Gumpeni N, Rink M, Cha EK, Karakiewicz PI, Scherr DS, Shariat SF.

BJU Int. 2012 Nov;110(10):1463-70. doi: 10.1111/j.1464-410X.2012.11129.x. Epub 2012 Apr 13. Review.

49.

Biomolecular predictors of urothelial cancer behavior and treatment outcomes.

Rink M, Cha EK, Green D, Hansen J, Robinson BD, Lotan Y, Sagalowsky AI, Chun FK, Karakiewicz PI, Fisch M, Scherr DS, Shariat SF.

Curr Urol Rep. 2012 Apr;13(2):122-35. doi: 10.1007/s11934-012-0237-1. Review.

PMID:
22354565
50.

Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery.

Rink M, Ehdaie B, Cha EK, Green DA, Karakiewicz PI, Babjuk M, Margulis V, Raman JD, Svatek RS, Fajkovic H, Lee RK, Novara G, Hansen J, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Pycha A, Fisch M, Scherr DS, Shariat SF; Bladder Cancer Research Consortium (BCRC); Upper Tract Urothelial Carcinoma Collaboration (UTUCC).

Eur Urol. 2012 Oct;62(4):677-84. Epub 2012 Feb 15.

PMID:
22349570

Supplemental Content

Support Center